SelectQuote earnings release, May 5, 2026

SelectQuote, Inc. (SLQT) · Form 8-K, Item 2.02 · Filed · SEC filing

SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results

Third Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights

• Revenue of $430.9 million

• Net income of $40.2 million

• Adjusted EBITDA* of $44.6 million

Fiscal Year 2026 Guidance Ranges:

• Revenue expected in a range of $1.61 billion to $1.71 billion

• Adjusted EBITDA* expected in a range of $90 million to $100 million

Third Quarter Fiscal Year 2026 – Segment Highlights

Senior

• Revenue of $182.9 million

• Adjusted EBITDA of $58.6 million

• Approved Medicare Advantage policies of 175,557

Healthcare Services

• Revenue of $199.4 million

• Adjusted EBITDA of $5.3 million

• 116,616 SelectRx members

Life

• Revenue of $47.9 million

• Adjusted EBITDA of $6.1 million

OVERLAND PARK, Kan., May 5, 2026--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the third quarter of fiscal year 2026 of $430.9 million compared to consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million. Consolidated net income for the third quarter of fiscal year 2026 was $40.2 million compared to consolidated net income for the third quarter of fiscal year 2025 of $26.0 million. Finally, consolidated Adjusted EBITDA* for the third quarter of fiscal year 2026 was $44.6 million compared to consolidated Adjusted EBITDA* for the third quarter of fiscal year 2025 of $37.7 million.

SelectQuote Chief Executive Officer Tim Danker remarked, “SelectQuote delivered consistent profit and cash flow for another quarter, despite market shifts for both Medicare Advantage and prescription drugs. We reaffirm our financial outlook for fiscal 2026 driven by operating execution by our agents and continued leverage of our information and technology advantages. Revenue to customer acquisition cost of 6.7X represented a high water mark for the company, and more importantly, signals the value our differentiated healthcare service model provides to policyholders and prescription drug customers.”

Mr. Danker continued, “Our goal to drive reliable and consistent profit, and cash flow growth remains priority number one. We believe the improvement to our capital structure to date, combined with the continued maturation of our SelectRx business, positions SelectQuote to materially expand cash flow in the years ahead. We continue to grow our receivables balance, which now stands at nearly $1 billion and grew by nearly $50 million over the past year, including a $14 million positive change in estimate reflective of the durability and dependability of these future cash flows.”

* See “Non-GAAP Financial Measures” below.¹

Segment Results

We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount.

Senior

Financial Results

The following table provides the financial results for the Senior segment for the periods presented:

Operating Metrics

Submitted Policies

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

Financial statements

Income Statement

Twelve Months Ended March 31,

Twelve Months Ended March 31, – 2026Twelve Months Ended March 31, – 2025
MA and MS approved policies582,951616,379
MA and MS commission per MA / MS policy868885
Other commission per MA/MS policy1113
Pharmacy revenue per MA/MS policy1,4611,063
Other revenue per MA/MS policy150103
Total revenue per MA / MS policy2,4902,064
Total operating expenses per MA / MS policy-2,193-1,794
Adjusted EBITDA per MA/MS policy297270
Adjusted EBITDA Margin per MA/MS policy1213
Revenue / CAC multiple6.7X5.8X

Income Statement

Three Months Ended March 31, — (In thousands) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025Nine Months Ended March 31, – 2026Nine Months Ended March 31, – 2025
REVENUE:Commissions and other services235,663222,889655,823663,338
REVENUE:Pharmacy195,270185,271641,023518,154
REVENUE:Total revenue430,933408,1601,296,8461,181,492
OPERATING COSTS AND EXPENSES:Cost of commissions and other services revenue83,26879,412255,403246,283
OPERATING COSTS AND EXPENSES:Cost of goods sold—pharmacy revenue171,289162,304569,262448,029
OPERATING COSTS AND EXPENSES:Marketing and advertising92,48192,733259,456254,222
OPERATING COSTS AND EXPENSES:Selling, general, and administrative38,18841,685112,948122,850
OPERATING COSTS AND EXPENSES:Technical development9,7779,96729,28329,086
OPERATING COSTS AND EXPENSES:Total operating costs and expenses395,003386,1011,226,3521,100,470
OPERATING COSTS AND EXPENSES:INCOME FROM OPERATIONS35,93022,05970,49481,022
OPERATING COSTS AND EXPENSES:INTEREST EXPENSE, NET-10,602-20,407-34,023-67,160
OPERATING COSTS AND EXPENSES:CHANGE IN FAIR VALUE OF WARRANTS27,48932,98661,82125,344
OPERATING COSTS AND EXPENSES:LOSS ON EXTINGUISHMENT OF DEBT-8,659-8,659
OPERATING COSTS AND EXPENSES:OTHER EXPENSE, NET-34-37-216-70
OPERATING COSTS AND EXPENSES:INCOME BEFORE INCOME TAX EXPENSE44,12434,60189,41739,136
OPERATING COSTS AND EXPENSES:INCOME TAX EXPENSE3,9278,57910,3864,424
OPERATING COSTS AND EXPENSES:NET INCOME40,19726,02279,03134,712
OPERATING COSTS AND EXPENSES:Senior Non-Convertible Preferred Stock accumulated dividends and accretion-18,775-5,787-54,382-5,787
OPERATING COSTS AND EXPENSES:NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS21,42220,23524,64928,925
NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:Basic0.110.110.130.17
NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:Diluted0.110.030.110.13
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:Basic189,455178,156187,614173,462
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:Diluted190,481186,639190,647178,895

Income Statement

Three Months Ended March 31, 2026 — (Unaudited) (in thousands)

Three Months Ended March 31, 2026 – SeniorThree Months Ended March 31, 2026 – Healthcare ServicesThree Months Ended March 31, 2026 – LifeThree Months Ended March 31, 2026 – Total
Total revenue from reportable segments182,890199,38647,896430,172
Less:Cost of commissions and other services revenue-54,596-6,976-18,465
Less:Cost of goods sold - pharmacy revenue-169,814
Less:Marketing expense-69,060-1,686-23,131
Less:Technical development-318
Less:Selling, general, and administrative-592-15,314-216
Less:Adjusted Segment EBITDA58,6425,2786,08470,004
Reconciliation of total segment Adjusted EBITDAAll other Adjusted EBITDA1,376
Reconciliation of total segment Adjusted EBITDACorporate-26,790
Reconciliation of total segment Adjusted EBITDAShare-based compensation expense-3,678
Reconciliation of total segment Adjusted EBITDATransaction costs-631
Reconciliation of total segment Adjusted EBITDADepreciation and amortization-4,385
Reconciliation of total segment Adjusted EBITDALoss on extinguishment of debt-8,659
Reconciliation of total segment Adjusted EBITDAChange in fair value of warrants27,489
Reconciliation of total segment Adjusted EBITDAInterest expense, net-10,602
Reconciliation of total segment Adjusted EBITDAIncome before income tax expense44,124

Income Statement

Three Months Ended March 31, 2025 — (Unaudited) (in thousands)

Three Months Ended March 31, 2025 – SeniorThree Months Ended March 31, 2025 – Healthcare ServicesThree Months Ended March 31, 2025 – LifeThree Months Ended March 31, 2025 – Total
Total revenue from reportable segments169,442189,56945,842404,853
Less:Cost of commissions and other services revenue-53,374-5,816-17,415
Less:Cost of goods sold - pharmacy revenue-161,026
Less:Marketing expense-69,808-1,939-21,789
Less:Technical development-491
Less:Selling, general, and administrative-559-13,852-274
Less:Adjusted Segment EBITDA45,7016,4456,36458,510
Reconciliation of total segment Adjusted EBITDAAll other Adjusted EBITDA3,549
Reconciliation of total segment Adjusted EBITDACorporate-24,336
Reconciliation of total segment Adjusted EBITDAShare-based compensation expense-4,960
Reconciliation of total segment Adjusted EBITDATransaction costs-5,813
Reconciliation of total segment Adjusted EBITDADepreciation and amortization-4,925

Income Statement

Nine Months Ended March 31, 2026 — (Unaudited) (in thousands)

Nine Months Ended March 31, 2026 – SeniorNine Months Ended March 31, 2026 – Healthcare ServicesNine Months Ended March 31, 2026 – LifeNine Months Ended March 31, 2026 – Total
Total revenue from reportable segments503,426651,391138,1661,292,983
Less:Cost of commissions and other services revenue-170,884-21,635-53,848
Less:Cost of goods sold - pharmacy revenue-564,995
Less:Marketing expense-190,746-6,309-66,267
Less:Technical development-1,068
Less:Selling, general, and administrative-1,739-44,048-815
Less:Adjusted Segment EBITDA140,05713,33617,236170,629
Reconciliation of total segment Adjusted EBITDAAll other Adjusted EBITDA5,366
Reconciliation of total segment Adjusted EBITDACorporate-78,752
Reconciliation of total segment Adjusted EBITDAShare-based compensation expense-11,480
Reconciliation of total segment Adjusted EBITDATransaction costs-1,478
Reconciliation of total segment Adjusted EBITDADepreciation and amortization-13,007
Reconciliation of total segment Adjusted EBITDAImpairment of equity-method investment-1,000
Reconciliation of total segment Adjusted EBITDALoss on extinguishment of debt-8,659
Reconciliation of total segment Adjusted EBITDAChange in fair value of warrants61,821
Reconciliation of total segment Adjusted EBITDAInterest expense, net-34,023
Reconciliation of total segment Adjusted EBITDAIncome before income tax expense89,417

Income Statement

Nine Months Ended March 31, 2025 — (Unaudited) (in thousands)

Nine Months Ended March 31, 2025 – SeniorNine Months Ended March 31, 2025 – Healthcare ServicesNine Months Ended March 31, 2025 – LifeNine Months Ended March 31, 2025 – Total
Total revenue from reportable segments517,930528,677124,9931,171,600
Less:Cost of commissions and other services revenue-169,543-19,627-47,028
Less:Cost of goods sold - pharmacy revenue-444,401
Less:Marketing expense-192,583-6,088-57,456
Less:Technical development-1,691
Less:Selling, general, and administrative-1,855-43,336-762
Less:Adjusted Segment EBITDA153,94913,53419,747187,230
Reconciliation of total segment Adjusted EBITDAAll other Adjusted EBITDA9,645
Reconciliation of total segment Adjusted EBITDACorporate-73,316
Reconciliation of total segment Adjusted EBITDAShare-based compensation expense-13,505
Reconciliation of total segment Adjusted EBITDATransaction costs-13,358
Reconciliation of total segment Adjusted EBITDADepreciation and amortization-15,584
Reconciliation of total segment Adjusted EBITDALoss on disposal of property, equipment, and software, net-160
Reconciliation of total segment Adjusted EBITDAChange in fair value of warrants25,344
Reconciliation of total segment Adjusted EBITDAInterest expense, net-67,160
Reconciliation of total segment Adjusted EBITDAIncome before income tax expense39,136

Income Statement

Three Months Ended March 31, — (Unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025Nine Months Ended March 31, – 2026Nine Months Ended March 31, – 2025
Net income40,19726,02279,03134,712
Share-based compensation expense3,6784,96011,48013,505
Transaction costs6315,8131,47813,358
Depreciation and amortization4,3854,92513,00715,584
Loss on disposal of property, equipment, and software, net3160
Impairment of equity-method investment1,000
Loss on extinguishment of debt8,6598,659
Change in fair value of warrants-27,489-32,986-61,821-25,344
Interest expense, net10,60220,40734,02367,160
Income tax expense3,9278,57910,3864,424
Adjusted EBITDA44,59037,72397,243123,559

Balance Sheet

March 31, 2026 — (In thousands) (in thousands)

March 31, 2026June 30, 2025
CURRENT ASSETS:Cash, cash equivalents, and restricted cash35,21135,733
CURRENT ASSETS:Accounts receivable, net of allowances of $9.2 million and $11.8 million, respectively234,291151,388
CURRENT ASSETS:Commissions receivable-current76,836132,077
CURRENT ASSETS:Other current assets20,90021,844
CURRENT ASSETS:Total current assets367,238341,042
CURRENT ASSETS:COMMISSIONS RECEIVABLE—Net882,693818,751
CURRENT ASSETS:PROPERTY AND EQUIPMENT—Net13,24714,577
CURRENT ASSETS:SOFTWARE—Net16,95315,060
CURRENT ASSETS:OPERATING LEASE RIGHT-OF-USE ASSETS21,56624,635
CURRENT ASSETS:INTANGIBLE ASSETS—Net1,1201,973
CURRENT ASSETS:GOODWILL29,43829,438
CURRENT ASSETS:OTHER ASSETS2,4553,880
CURRENT ASSETS:TOTAL ASSETS1,334,7101,249,356
CURRENT LIABILITIES:Accounts payable103,20559,205
CURRENT LIABILITIES:Accrued expenses24,09213,856
CURRENT LIABILITIES:Accrued compensation and benefits68,64658,788
CURRENT LIABILITIES:Operating lease liabilities—current4,6654,820
CURRENT LIABILITIES:Current portion of long-term debt22,45768,523
CURRENT LIABILITIES:Other current liabilities8,0357,718
CURRENT LIABILITIES:Total current liabilities231,100212,910

Balance Sheet

March 31, 2026 — (In thousands) (in thousands)

March 31, 2026June 30, 2025
PREFERRED STOCK:Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively, current liquidation preference of $408.4 million and $367.1 million as of March 31, 2026 and June 30, 2025.278,757224,374
SHAREHOLDERS’ EQUITY:Common stock, $0.01 par value1,7631,728
SHAREHOLDERS’ EQUITY:Additional paid-in capital526,129571,605
SHAREHOLDERS’ EQUITY:Accumulated deficit-143,158-222,189
SHAREHOLDERS’ EQUITY:Total shareholders’ equity384,734351,144
SHAREHOLDERS’ EQUITY:TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY1,334,7101,249,356

Cash Flow

Nine Months Ended March 31, — (In thousands) (in thousands)

Nine Months Ended March 31, – 2026Nine Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income79,03134,712
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Depreciation and amortization13,00715,584
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Loss on disposal of property, equipment, and software160
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Impairment of equity-method investment1,000
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Loss on extinguishment of debt8,659
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Share-based compensation expense11,48013,505
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Deferred income taxes7,3404,424
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Amortization of debt issuance costs and debt discount3,3433,880
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Write-off of debt issuance costs93
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Accrued interest payable in kind13,301
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Change in fair value of warrants-61,821-25,344
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Non-cash lease expense3,0702,849
Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:Bad debt expense4,203
Changes in operating assets and liabilities:Accounts receivable, net-82,903-39,047
Changes in operating assets and liabilities:Commissions receivable-8,702-33,765
Changes in operating assets and liabilities:Other assets1,261-343
Changes in operating assets and liabilities:Accounts payable and accrued expenses53,58341,163
Changes in operating assets and liabilities:Operating lease liabilities-3,459-3,574
Changes in operating assets and liabilities:Other liabilities10,315-5,985
Changes in operating assets and liabilities:Net cash provided by operating activities35,20425,816
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property and equipment-3,093-1,690
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of software and capitalized software development costs-8,490-6,513
CASH FLOWS FROM INVESTING ACTIVITIES:Net cash used in investing activities-11,583-8,203
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from revolving credit facility270,000166,900
CASH FLOWS FROM FINANCING ACTIVITIES:Payments on revolving credit facility-270,000-166,900
CASH FLOWS FROM FINANCING ACTIVITIES:Net proceeds from Term Loan315,234
CASH FLOWS FROM FINANCING ACTIVITIES:Payments on Term Loans-314,000-384,644
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from ABS Notes99,095
CASH FLOWS FROM FINANCING ACTIVITIES:Payments on ABS Notes-15,016-11,723
CASH FLOWS FROM FINANCING ACTIVITIES:Payments on other debt-380-202
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from common stock options exercised and employee stock purchase plan112
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from issuance of Senior Non-Convertible Preferred Stock337,855
CASH FLOWS FROM FINANCING ACTIVITIES:Senior Non-Convertible Preferred Stock issuance costs-7,076
CASH FLOWS FROM FINANCING ACTIVITIES:Payments of tax withholdings related to net share settlement of equity awards-2,539-5,019
CASH FLOWS FROM FINANCING ACTIVITIES:Payments of debt issuance costs-7,730-2,479
CASH FLOWS FROM FINANCING ACTIVITIES:Net cash (used in) provided by financing activities-24,43125,919
CASH FLOWS FROM FINANCING ACTIVITIES:NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH-81043,532
CASH FLOWS FROM FINANCING ACTIVITIES:CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period37,06642,690
CASH FLOWS FROM FINANCING ACTIVITIES:CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period36,25686,222
Full release

(1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

Approved Policies

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

The following table shows the number of approved policies for the periods presented:

(1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.²

Lifetime Value of Commissions per Approved Policy

Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

The following table shows the lifetime value of commissions per approved policy for the periods presented:

(1) Represents the weighted average LTV per approved policy.

Healthcare Services

Financial Results

The following table provides the financial results for the Healthcare Services segment for the periods presented:

Operating Metrics

Members

The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

The following table shows the total number of SelectRx members as of the periods presented:

The total number of SelectRx members increased by 11% as of March 31, 2026, compared to March 31, 2025, due to our strategy to grow SelectRx membership.... (truncated)sented:³

Combined Senior and Healthcare Services - Consumer Per Unit Economics

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

Total revenue per MA/MS policy increased 21% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 22% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

Life

Financial Results

The following table provides the financial results for the Life segment for the periods presented:⁴

Operating Metrics

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

The following table shows term and final expense premiums for the periods presented:

Earnings Conference Call

SelectQuote, Inc. will host a conference call with the investment community on May 5, 2026 beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://events.q4inc.com/analyst/775360431?pwd=VqmW7XWK. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income. We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.... (truncated)ion included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company’s GAAP financial results.⁵

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About SelectQuote:... (truncated)llars underpin SelectQuote’s success: a strong force of highly-trained and skilled⁶ agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:

Sloan Bohlen

877-678-4083 investorrelations@selectquote.com

Media:

Matt Gunter

913-286-4931 matt.gunter@selectquote.com

Source: SelectQuote, Inc.⁷

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · SelectQuote earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.